Israel - English - Ministry of Health

novartis israel ltd - alpelisib - film coated tablets - alpelisib 200 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

Israel - English - Ministry of Health

novartis israel ltd - alpelisib - film coated tablets - alpelisib 50 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

Israel - English - Ministry of Health

novartis israel ltd - brolucizumab - solution for injection - brolucizumab 120 mg / 1 ml - brolucizumab - beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (amd).

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - ofatumumab -

Israel - English - Ministry of Health

novartis israel ltd - crizanlizumab - concentrate for solution for infusion - crizanlizumab 10 mg/ml - crizanlizumab - adakveo is indicated to reduce the frequency of vasoocclusive crises (vocs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - secukinumab -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - secukinumab -

Israel - English - Ministry of Health

novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 20 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation

Israel - English - Ministry of Health

novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 40 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - glycopyrronium bromide 0.063mg equivalent to glycopyrronium 0.05 mg;   - powder filled inhalation capsule - 50 mcg - active: glycopyrronium bromide 0.063mg equivalent to glycopyrronium 0.05 mg   excipient: lactose monohydrate magnesium stearate orange capsule (novartis) - once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).